<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00803049</url>
  </required_header>
  <id_info>
    <org_study_id>LTS6050</org_study_id>
    <secondary_id>2006-003361-14</secondary_id>
    <nct_id>NCT00803049</nct_id>
  </id_info>
  <brief_title>Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis</brief_title>
  <official_title>Long-term Extension of the Multinational, Double-blind, Placebo Controlled Study EFC6049 (HMR1726D/3001) to Document the Safety of Two Doses of Teriflunomide (7 and 14 mg) in Patients With Multiple Sclerosis With Relapses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study was to document the long-term safety and tolerability of
      teriflunomide in Multiple Sclerosis (MS) participants with relapse.

      The secondary objective was to document the long-term efficacy on disability progression,
      relapse rate and Magnetic Resonance Imaging (MRI) parameters.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants completing the EFC6049 (HMR1726D/3001) study were given the opportunity to
      continue in the extension study;

        -  participants receiving teriflunomide 7 mg or 14 mg were blindly maintained on the same
           dose of teriflunomide.

        -  participants receiving placebo were randomized at a 1:1 ratio to teriflunomide 7 mg or
           14 mg.

      The study period per participant was broken down as follows:

        -  Double-blind treatment: up to a maximum of 288 weeks or until teriflunomide was
           commercially available in the country where participant lived,

        -  Post-washout follow-up: 4 weeks after last treatment intake. No post-washout follow up
           if participant continued on teriflunomide treatment by obtaining its commercial form
           after end of the study.

      The total duration of the extension was 292 weeks (about 6 years) from the first participant
      enrolled or until teriflunomide is commercially available in the country where participant
      lived.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Baseline (LTS6050) up to 28 days after last dose of study drug up to 450 weeks</time_frame>
    <description>Adverse event (AE) was defined as any untoward medical occurrence in a participant who received investigational medicinal product (IMP) without regard to possibility of causal relationship with this treatment. TEAEs: AEs that developed or worsened or became serious during on-treatment period which was defined as the period from the time of first dose of study drug (in LTS6050) up to 4 weeks (28 days) after last dose of study drug. Serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included both serious and non-serious AEs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to 12 Week Sustained Disability Progression (DP): Kaplan-Meier Estimates of the Rate of DP</measure>
    <time_frame>Up to 10.8 years (EFC6049: 108 weeks + LTS6050: 450 weeks)</time_frame>
    <description>Sustained DP defined as sustained increase of at least 1 point from baseline (EFC6049) expanded disability status scale (EDSS) score (0.5 point for participants with baseline EDSS&gt;5.5) persisting for at least 12 weeks. EDSS: an ordinal scale qualifies disability in participants with MS. EDSS total score range: 0 (normal neurological examination) to 10 (death due to Multiple Sclerosis [MS]). Probability of DP at 12 weeks was estimated using Kaplan-Meier method on time to DP defined as date of first DP minus (-) date of randomization in EFC6049 study +1 day. Participants free of DP (no DP observed on treatment) were censored at the date of last on-treatment EDSS evaluation in LTS6050. Kaplan-Meier method consists in computing probabilities of non-occurrence of event at any observed time of event and multiplying successive probabilities for time ≤t by any earlier computed probabilities to estimate the probability of being event-free for the amount of time t.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 24 Week Sustained Disability Progression (DP): Kaplan-Meier Estimates of the Rate of DP</measure>
    <time_frame>Up to 10.8 years (EFC6049: 108 weeks + LTS6050: 450 weeks)</time_frame>
    <description>Sustained DP was defined as sustained increase of at least 1 point from baseline (EFC6049) EDSS score (0.5 point for participants with baseline EDSS&gt;5.5) persisting for at least 24 weeks. EDSS: an ordinal scale qualifies disability in participants with MS. EDSS total score range: 0 (normal neurological examination) to 10 (death due to MS). Probability of DP at 24 weeks was estimated using Kaplan-Meier method on time to DP defined as date of first DP minus (-) date of randomization in EFC6049 study +1 day. Participants free of DP (no DP observed on treatment) were censored at the date of last on-treatment EDSS evaluation in LTS6050. Kaplan-Meier method consists in computing probabilities of non-occurrence of event at any observed time of event and multiplying successive probabilities for time ≤t by any earlier computed probabilities to estimate the probability of being event-free for the amount of time t.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Free of Sustained Disability Progression (DP)</measure>
    <time_frame>Up to 10.8 years since EFC6049 randomization (EFC6049: 108 weeks + LTS6050: 450 weeks)</time_frame>
    <description>Sustained DP was defined as sustained increase of at least 1 point from baseline (EFC6049) EDSS score (0.5 point for participants with baseline EDSS&gt;5.5) persisting for at least 12 weeks and 24 weeks. EDSS is an ordinal scale in half-point increments that qualifies disability in participants with MS. It consists of 8 ordinal rating scales assessing seven functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder, cerebral) as well as ambulation. EDSS total score ranges from 0 (normal neurological examination) to 10 (death due to MS), where higher scores indicates worse neurological function. Percentage of participants who were considered as free of disability progression confirmed after 12 week sustained progression and 24 week sustained progression were reported. Analysis for this outcome measure was performed on combined data of EFC6049 and LTS6050 study, as pre-specified in protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized MS Relapse Rate (ARR): Poisson Regression Estimates</measure>
    <time_frame>Up to 8 years since LTS6050 randomization</time_frame>
    <description>ARR was obtained from total number of confirmed relapses that occurred during treatment period divided by sum of treatment durations in LTS6050 study only. Each episode of relapse - appearance, or worsening of a clinical symptom that was stable for at least 30 days, that persisted for a minimum of 24 hours in the absence of fever was to be confirmed by an increase in EDSS score or Functional System (FS) scores. EDSS: an ordinal scale qualifies disability. EDSS total score range: 0 (normal neurological examination) to 10 (death due to MS). FSS: to assess the neurological function. Total score range: 0 (normal) - 6(worse), higher scores = worse neurological function. To account for the different treatment duration among participants, a Poisson regression model with robust error variance was used (total number of confirmed relapses as response variable; log transformed treatment duration as &quot;offset&quot; variable; treatment group, region of enrolment and baseline EDSS stratum as covariates).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnetic Resonance Imaging (MRI) Assessment: Change From Baseline in Total Volume of Abnormal Lesions (Burden of Disease [BOD]) at Week 192 Since LTS6050 Randomization</measure>
    <time_frame>Baseline, Week 192</time_frame>
    <description>BOD was assessed by cerebral MRI and defined as the total volume of all abnormal brain tissue (calculated as the sum of the total volume of T2-lesion component and T1-hypointense lesion component).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">742</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Placebo/Teriflunomide 7 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who completed treatment of placebo (for teriflunomide) tablet once daily (QD) for 108 weeks in EFC6049 study, received teriflunomide tablet 7 mg QD for 288 weeks in this extension study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Teriflunomide 7 mg/7 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who completed treatment of teriflunomide 7 mg tablet QD for 108 weeks in EFC6049 study, continued their treatment with teriflunomide 7 mg tablet QD for 288 weeks in this extension study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/Teriflunomide 14 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who completed treatment of placebo (for teriflunomide) tablet QD for 108 weeks in EFC6049, study received teriflunomide 14 mg tablet QD for 288 weeks in this extension study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Teriflunomide 14 mg/14 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who completed treatment of teriflunomide 14 mg tablet QD for 108 weeks in EFC6049 study, continued their treatment with teriflunomide 14 mg tablet QD for 288 weeks in this extension study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriflunomide (HMR1726)</intervention_name>
    <description>Tablet, oral administration QD.</description>
    <arm_group_label>Placebo/Teriflunomide 7 mg</arm_group_label>
    <arm_group_label>Teriflunomide 7 mg/7 mg</arm_group_label>
    <arm_group_label>Placebo/Teriflunomide 14 mg</arm_group_label>
    <arm_group_label>Teriflunomide 14 mg/14 mg</arm_group_label>
    <other_name>Aubagio</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant who completed the previous double-blind placebo-controlled study EFC6049
             and who did not meet criteria for treatment withdrawal.

          -  Willingness to participate in a long-term safety/efficacy trial.

        Exclusion Criteria:

          -  Any known condition or circumstance that would prevent in the investigator's opinion,
             compliance or completion of the study.

        The above information is not intended to contain all considerations relevant to a
        participant's potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 1032</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1038</name>
      <address>
        <city>Ft. Wayne</city>
        <state>Indiana</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1033</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1037</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1603</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1604</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1601</name>
      <address>
        <city>Wien</city>
        <zip>1010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1602</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1208</name>
      <address>
        <city>Calgary</city>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1212</name>
      <address>
        <city>Gatineau</city>
        <zip>J9J 0A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1205</name>
      <address>
        <city>Greenfield Park</city>
        <zip>J4V 2J2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1201</name>
      <address>
        <city>Halifax</city>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1206</name>
      <address>
        <city>London</city>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1203</name>
      <address>
        <city>Montreal</city>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1204</name>
      <address>
        <city>Ottawa</city>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1202</name>
      <address>
        <city>Quebec</city>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1211</name>
      <address>
        <city>St. John'S</city>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1209</name>
      <address>
        <city>Toronto</city>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1210</name>
      <address>
        <city>Vancouver</city>
        <zip>V6T 2B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1207</name>
      <address>
        <city>Winnipeg</city>
        <zip>R3A 1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3804</name>
      <address>
        <city>Santiago</city>
        <zip>750-0710</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3802</name>
      <address>
        <city>Santiago</city>
        <zip>760-0746</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3803</name>
      <address>
        <city>Santiago</city>
        <zip>890-0085</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3801</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3805</name>
      <address>
        <city>Viña Del Mar</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4101</name>
      <address>
        <city>Olomouc</city>
        <zip>77520</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4801</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4804</name>
      <address>
        <city>Sønderborg</city>
        <zip>6400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4802</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1502</name>
      <address>
        <city>Tallinn</city>
        <zip>10617</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1501</name>
      <address>
        <city>Tartu</city>
        <zip>50406</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2203</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2206</name>
      <address>
        <city>Pori</city>
        <zip>28100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2201</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2202</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2415</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2403</name>
      <address>
        <city>Clermont Ferrand Cedex 1</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2408</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2413</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2404</name>
      <address>
        <city>Limoges Cedex</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2401</name>
      <address>
        <city>Lyon Cedex 03</city>
        <zip>69394</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2409</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2402</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2405</name>
      <address>
        <city>Nancy Cedex</city>
        <zip>54036</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2414</name>
      <address>
        <city>Nantes Cedex 01</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2407</name>
      <address>
        <city>Nice Cedex</city>
        <zip>06002</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2410</name>
      <address>
        <city>Paris Cedex 12</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2406</name>
      <address>
        <city>Rennes Cedex</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2411</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2011</name>
      <address>
        <city>Berlin</city>
        <zip>10785</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2001</name>
      <address>
        <city>Berlin</city>
        <zip>13347</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2000</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2012</name>
      <address>
        <city>Erbach</city>
        <zip>64711</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2004</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2005</name>
      <address>
        <city>Gießen</city>
        <zip>35385</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2007</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2008</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2010</name>
      <address>
        <city>Offenbach</city>
        <zip>63069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2009</name>
      <address>
        <city>Rostock</city>
        <zip>18055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2003</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65191</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2819</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2827</name>
      <address>
        <city>Fidenza</city>
        <zip>43036</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2803</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2814</name>
      <address>
        <city>Gallarate</city>
        <zip>21013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2808</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2812</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2809</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2813</name>
      <address>
        <city>Roma</city>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2824</name>
      <address>
        <city>Roma</city>
        <zip>00185</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4602</name>
      <address>
        <city>'S Hertogenbosch</city>
        <zip>5223 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4605</name>
      <address>
        <city>Breda</city>
        <zip>4818 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4601</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4604</name>
      <address>
        <city>Sittard-Geleen</city>
        <zip>6162 BG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3601</name>
      <address>
        <city>Oslo</city>
        <zip>0407</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3604</name>
      <address>
        <city>Tønsberg</city>
        <zip>3116</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3008</name>
      <address>
        <city>Bialystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3009</name>
      <address>
        <city>Bialystok</city>
        <zip>15-402</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3007</name>
      <address>
        <city>Gdansk</city>
        <zip>80-803</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3005</name>
      <address>
        <city>Lodz</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3006</name>
      <address>
        <city>Lublin</city>
        <zip>20-718</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3004</name>
      <address>
        <city>Lublin</city>
        <zip>20-954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3001</name>
      <address>
        <city>Poznan</city>
        <zip>60-355</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3002</name>
      <address>
        <city>Warszawa</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3003</name>
      <address>
        <city>Warszawa</city>
        <zip>02-957</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4201</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4203</name>
      <address>
        <city>Lisboa</city>
        <zip>1169-050</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3203</name>
      <address>
        <city>Moscow</city>
        <zip>119049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3205</name>
      <address>
        <city>Moscow</city>
        <zip>125015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3207</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3208</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3201</name>
      <address>
        <city>St-Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3202</name>
      <address>
        <city>St-Petersburg</city>
        <zip>197089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3206</name>
      <address>
        <city>St-Petersburg</city>
        <zip>197376</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3401</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1802</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 5003</name>
      <address>
        <city>Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 5006</name>
      <address>
        <city>Izmir</city>
        <zip>35380</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 5005</name>
      <address>
        <city>Kocaeli</city>
        <zip>41380</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 5001</name>
      <address>
        <city>Sihhiye / Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3504</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49027</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3505</name>
      <address>
        <city>Ivano-Frankovsk</city>
        <zip>76008</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3506</name>
      <address>
        <city>Kharkiv</city>
        <zip>61018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3510</name>
      <address>
        <city>Kharkiv</city>
        <zip>61178</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3508</name>
      <address>
        <city>Lviv</city>
        <zip>79010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3502</name>
      <address>
        <city>Odessa</city>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3509</name>
      <address>
        <city>Uzhgorod</city>
        <zip>88018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3507</name>
      <address>
        <city>Vinnitsa</city>
        <zip>21005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3501</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2604</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2607</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2608</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2600</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2601</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2609</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2606</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2602</name>
      <address>
        <city>Stoke On Trent</city>
        <zip>ST4 7LN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2008</study_first_submitted>
  <study_first_submitted_qc>December 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2008</study_first_posted>
  <results_first_submitted>December 5, 2016</results_first_submitted>
  <results_first_submitted_qc>December 5, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 30, 2017</results_first_posted>
  <last_update_submitted>December 5, 2016</last_update_submitted>
  <last_update_submitted_qc>December 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Oral treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 117 centres in 21 countries between 16 October 2006 and 23 December 2015. A total of 742 participants who completed study EFC6049 (NCT00134563), entered in this extension study (LTS6050 [NCT00803049]).</recruitment_details>
      <pre_assignment_details>Participants who received placebo in EFC6049 study were randomized in 1:1 ratio to receive either teriflunomide 7 mg/day or 14 mg/day and, those who received teriflunomide 7 mg/day or 14 mg/day in EFC6049 (NCT00134563) received same double-blind treatment in this extension study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo/Teriflunomide 7 mg</title>
          <description>Participants who completed treatment of placebo (for teriflunomide) tablet once daily (QD) for 108 weeks in EFC6049 study, received teriflunomide tablet 7 mg QD for 288 weeks in this extension study.</description>
        </group>
        <group group_id="P2">
          <title>Teriflunomide 7 mg/7 mg</title>
          <description>Participants who completed treatment of teriflunomide 7 mg tablet QD for 108 weeks in EFC6049 study, continued their treatment with teriflunomide 7 mg tablet QD for 288 weeks in this extension study.</description>
        </group>
        <group group_id="P3">
          <title>Placebo/Teriflunomide 14 mg</title>
          <description>Participants who completed treatment of placebo (for teriflunomide) tablet QD for 108 weeks in EFC6049, study received teriflunomide 14 mg tablet QD for 288 weeks in this extension study.</description>
        </group>
        <group group_id="P4">
          <title>Teriflunomide 14 mg/14 mg</title>
          <description>Participants who completed treatment of teriflunomide 14 mg tablet QD for 108 weeks in EFC6049 study, continued their treatment with teriflunomide 14 mg tablet QD for 288 weeks in this extension study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="129">Randomized in extension study</participants>
                <participants group_id="P2" count="252">Randomized in extension study</participants>
                <participants group_id="P3" count="108">Randomized in extension study</participants>
                <participants group_id="P4" count="253">Randomized in extension study</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="129"/>
                <participants group_id="P2" count="252"/>
                <participants group_id="P3" count="108"/>
                <participants group_id="P4" count="251"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="129"/>
                <participants group_id="P2" count="254">Included 1 participant from Placebo/Teriflunomide 14 mg and 1 from Teriflunomide14 mg/14 mg arm</participants>
                <participants group_id="P3" count="107">1 participant received Teriflunomide 7 mg and analysed in Teriflunomide 7 mg/7 mg arm</participants>
                <participants group_id="P4" count="250">1 participant received Teriflunomide 7 mg and analysed in Teriflunomide 7 mg/7 mg arm</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="134"/>
                <participants group_id="P3" count="64"/>
                <participants group_id="P4" count="151"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="118"/>
                <participants group_id="P3" count="44"/>
                <participants group_id="P4" count="102"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="44"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized and Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other than Specified Above</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo/Teriflunomide 7 mg</title>
          <description>Participants who completed treatment of placebo (for teriflunomide) tablet once daily (QD) for 108 weeks in EFC6049 study, received teriflunomide tablet 7 mg QD for 288 weeks in this extension study.</description>
        </group>
        <group group_id="B2">
          <title>Teriflunomide 7 mg/7 mg</title>
          <description>Participants who completed treatment of teriflunomide 7 mg tablet QD for 108 weeks in EFC6049 study, continued their treatment with teriflunomide 7 mg tablet QD for 288 weeks in this extension study.</description>
        </group>
        <group group_id="B3">
          <title>Placebo/Teriflunomide 14 mg</title>
          <description>Participants who completed treatment of placebo (for teriflunomide) tablet QD for 108 weeks in EFC6049, study received teriflunomide 14 mg tablet QD for 288 weeks in this extension study.</description>
        </group>
        <group group_id="B4">
          <title>Teriflunomide 14 mg/14 mg</title>
          <description>Participants who completed treatment of teriflunomide 14 mg tablet QD for 108 weeks in EFC6049 study, continued their treatment with teriflunomide 14 mg tablet QD for 288 weeks in this extension study.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="129"/>
            <count group_id="B2" value="252"/>
            <count group_id="B3" value="108"/>
            <count group_id="B4" value="253"/>
            <count group_id="B5" value="742"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.6" spread="8.5"/>
                    <measurement group_id="B2" value="38.0" spread="8.8"/>
                    <measurement group_id="B3" value="37.6" spread="8.5"/>
                    <measurement group_id="B4" value="38.6" spread="8.4"/>
                    <measurement group_id="B5" value="38.4" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="175"/>
                    <measurement group_id="B3" value="85"/>
                    <measurement group_id="B4" value="182"/>
                    <measurement group_id="B5" value="536"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="71"/>
                    <measurement group_id="B5" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
        <description>Adverse event (AE) was defined as any untoward medical occurrence in a participant who received investigational medicinal product (IMP) without regard to possibility of causal relationship with this treatment. TEAEs: AEs that developed or worsened or became serious during on-treatment period which was defined as the period from the time of first dose of study drug (in LTS6050) up to 4 weeks (28 days) after last dose of study drug. Serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included both serious and non-serious AEs.</description>
        <time_frame>Baseline (LTS6050) up to 28 days after last dose of study drug up to 450 weeks</time_frame>
        <population>Safety population: all participants randomized in the LTS6050 study and exposed to IMP during the LTS6050 study treatment period, regardless of the amount of treatment administered. The safety analysis was conducted as the treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Teriflunomide 7 mg</title>
            <description>Participants who completed treatment of placebo (for teriflunomide) tablet QD for 108 weeks in EFC6049 study, received teriflunomide tablet 7 mg QD for 288 weeks in this extension study.</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 7 mg/7 mg</title>
            <description>Participants who completed treatment of teriflunomide 7 mg tablet QD for 108 weeks in EFC6049 study, continued their treatment with teriflunomide 7 mg tablet QD for 288 weeks in this extension study.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Teriflunomide 14 mg</title>
            <description>Participants who completed treatment of placebo (for teriflunomide) tablet QD for 108 weeks in EFC6049, study received teriflunomide 14 mg tablet QD for 288 weeks in this extension study.</description>
          </group>
          <group group_id="O4">
            <title>Teriflunomide 14 mg/14 mg</title>
            <description>Participants who completed treatment of teriflunomide 14 mg tablet QD for 108 weeks in EFC6049 study, continued their treatment with teriflunomide 14 mg tablet QD for 288 weeks in this extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
          <description>Adverse event (AE) was defined as any untoward medical occurrence in a participant who received investigational medicinal product (IMP) without regard to possibility of causal relationship with this treatment. TEAEs: AEs that developed or worsened or became serious during on-treatment period which was defined as the period from the time of first dose of study drug (in LTS6050) up to 4 weeks (28 days) after last dose of study drug. Serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included both serious and non-serious AEs.</description>
          <population>Safety population: all participants randomized in the LTS6050 study and exposed to IMP during the LTS6050 study treatment period, regardless of the amount of treatment administered. The safety analysis was conducted as the treatment received.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="254"/>
                <count group_id="O3" value="107"/>
                <count group_id="O4" value="250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.8"/>
                    <measurement group_id="O2" value="91.3"/>
                    <measurement group_id="O3" value="94.4"/>
                    <measurement group_id="O4" value="91.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Treatment Emergent SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8"/>
                    <measurement group_id="O2" value="28.0"/>
                    <measurement group_id="O3" value="21.5"/>
                    <measurement group_id="O4" value="24.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE Leading to Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3"/>
                    <measurement group_id="O2" value="0.8"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE Leading to Permanent Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.1"/>
                    <measurement group_id="O2" value="12.2"/>
                    <measurement group_id="O3" value="12.1"/>
                    <measurement group_id="O4" value="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to 12 Week Sustained Disability Progression (DP): Kaplan-Meier Estimates of the Rate of DP</title>
        <description>Sustained DP defined as sustained increase of at least 1 point from baseline (EFC6049) expanded disability status scale (EDSS) score (0.5 point for participants with baseline EDSS&gt;5.5) persisting for at least 12 weeks. EDSS: an ordinal scale qualifies disability in participants with MS. EDSS total score range: 0 (normal neurological examination) to 10 (death due to Multiple Sclerosis [MS]). Probability of DP at 12 weeks was estimated using Kaplan-Meier method on time to DP defined as date of first DP minus (-) date of randomization in EFC6049 study +1 day. Participants free of DP (no DP observed on treatment) were censored at the date of last on-treatment EDSS evaluation in LTS6050. Kaplan-Meier method consists in computing probabilities of non-occurrence of event at any observed time of event and multiplying successive probabilities for time ≤t by any earlier computed probabilities to estimate the probability of being event-free for the amount of time t.</description>
        <time_frame>Up to 10.8 years (EFC6049: 108 weeks + LTS6050: 450 weeks)</time_frame>
        <population>Intent-to-treat (ITT) (EFC6049+ LTS6050) population: all participants randomized in both EFC6049 and LTS6050 studies that had at least 1-day IMP exposure during both EFC6049 and LTS6050 studies. Analysis for this outcome measure was performed on the combined data of EFC6049 andLTS6050 study, as pre-specified in the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Teriflunomide 7 mg</title>
            <description>Participants who completed treatment of placebo (for teriflunomide) tablet QD for 108 weeks in EFC6049 study, received teriflunomide tablet 7 mg QD for 288 weeks in this extension study.</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 7 mg/7 mg</title>
            <description>Participants who completed treatment of teriflunomide 7 mg tablet QD for 108 weeks in EFC6049 study, continued their treatment with teriflunomide 7 mg tablet QD for 288 weeks in this extension study.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Teriflunomide 14 mg</title>
            <description>Participants who completed treatment of placebo (for teriflunomide) tablet QD for 108 weeks in EFC6049, study received teriflunomide 14 mg tablet QD for 288 weeks in this extension study.</description>
          </group>
          <group group_id="O4">
            <title>Teriflunomide 14 mg/14 mg</title>
            <description>Participants who completed treatment of teriflunomide 14 mg tablet QD for 108 weeks in EFC6049 study, continued their treatment with teriflunomide 14 mg tablet QD for 288 weeks in this extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to 12 Week Sustained Disability Progression (DP): Kaplan-Meier Estimates of the Rate of DP</title>
          <description>Sustained DP defined as sustained increase of at least 1 point from baseline (EFC6049) expanded disability status scale (EDSS) score (0.5 point for participants with baseline EDSS&gt;5.5) persisting for at least 12 weeks. EDSS: an ordinal scale qualifies disability in participants with MS. EDSS total score range: 0 (normal neurological examination) to 10 (death due to Multiple Sclerosis [MS]). Probability of DP at 12 weeks was estimated using Kaplan-Meier method on time to DP defined as date of first DP minus (-) date of randomization in EFC6049 study +1 day. Participants free of DP (no DP observed on treatment) were censored at the date of last on-treatment EDSS evaluation in LTS6050. Kaplan-Meier method consists in computing probabilities of non-occurrence of event at any observed time of event and multiplying successive probabilities for time ≤t by any earlier computed probabilities to estimate the probability of being event-free for the amount of time t.</description>
          <population>Intent-to-treat (ITT) (EFC6049+ LTS6050) population: all participants randomized in both EFC6049 and LTS6050 studies that had at least 1-day IMP exposure during both EFC6049 and LTS6050 studies. Analysis for this outcome measure was performed on the combined data of EFC6049 andLTS6050 study, as pre-specified in the protocol.</population>
          <units>Probability</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="252"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.544" lower_limit="0.441" upper_limit="0.646"/>
                    <measurement group_id="O2" value="0.494" lower_limit="0.423" upper_limit="0.565"/>
                    <measurement group_id="O3" value="0.627" lower_limit="0.444" upper_limit="0.811"/>
                    <measurement group_id="O4" value="0.473" lower_limit="0.403" upper_limit="0.543"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using Log-rank test with treatment, EDSS strata at baseline and region as covariates. Estimation was performed using Cox proportional hazard model with treatment, EDSS strata at baseline and region as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2079</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.824</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.602</ci_lower_limit>
            <ci_upper_limit>1.128</ci_upper_limit>
            <estimate_desc>Placebo/Teriflunomide 7 mg vs. Teriflunomide 7 mg/7 mg</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using Log-rank test with treatment, EDSS strata at baseline and region as covariates. Estimation was performed using Cox proportional hazard model with treatment, EDSS strata at baseline and region as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3039</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.825</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.591</ci_lower_limit>
            <ci_upper_limit>1.152</ci_upper_limit>
            <estimate_desc>Placebo/Teriflunomide 14 mg vs.Teriflunomide 14 mg/14 mg</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using Log-rank test with treatment, EDSS strata at baseline and region as covariates. Estimation was performed using Cox proportional hazard model with treatment, EDSS strata at baseline and region as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8271</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.963</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.736</ci_lower_limit>
            <ci_upper_limit>1.260</ci_upper_limit>
            <estimate_desc>Teriflunomide 7 mg/7 mg vs. Teriflunomide 14 mg/14 mg</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to 24 Week Sustained Disability Progression (DP): Kaplan-Meier Estimates of the Rate of DP</title>
        <description>Sustained DP was defined as sustained increase of at least 1 point from baseline (EFC6049) EDSS score (0.5 point for participants with baseline EDSS&gt;5.5) persisting for at least 24 weeks. EDSS: an ordinal scale qualifies disability in participants with MS. EDSS total score range: 0 (normal neurological examination) to 10 (death due to MS). Probability of DP at 24 weeks was estimated using Kaplan-Meier method on time to DP defined as date of first DP minus (-) date of randomization in EFC6049 study +1 day. Participants free of DP (no DP observed on treatment) were censored at the date of last on-treatment EDSS evaluation in LTS6050. Kaplan-Meier method consists in computing probabilities of non-occurrence of event at any observed time of event and multiplying successive probabilities for time ≤t by any earlier computed probabilities to estimate the probability of being event-free for the amount of time t.</description>
        <time_frame>Up to 10.8 years (EFC6049: 108 weeks + LTS6050: 450 weeks)</time_frame>
        <population>Intent-to-treat (ITT) (EFC6049+ LTS6050) population: all participants randomized in both EFC6049 and LTS6050 studies that had at least 1-day IMP exposure during both EFC6049 and LTS6050 studies. Analysis for this outcome measure was performed on the combined data of EFC6049 andLTS6050 study, as pre-specified in the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Teriflunomide 7 mg</title>
            <description>Participants who completed treatment of placebo (for teriflunomide) tablet QD for 108 weeks in EFC6049 study, received teriflunomide tablet 7 mg QD for 288 weeks in this extension study.</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 7 mg/7 mg</title>
            <description>Participants who completed treatment of teriflunomide 7 mg tablet QD for 108 weeks in EFC6049 study, continued their treatment with teriflunomide 7 mg tablet QD for 288 weeks in this extension study.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Teriflunomide 14 mg</title>
            <description>Participants who completed treatment of placebo (for teriflunomide) tablet QD for 108 weeks in EFC6049, study received teriflunomide 14 mg tablet QD for 288 weeks in this extension study.</description>
          </group>
          <group group_id="O4">
            <title>Teriflunomide 14 mg/14 mg</title>
            <description>Participants who completed treatment of teriflunomide 14 mg tablet QD for 108 weeks in EFC6049 study, continued their treatment with teriflunomide 14 mg tablet QD for 288 weeks in this extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to 24 Week Sustained Disability Progression (DP): Kaplan-Meier Estimates of the Rate of DP</title>
          <description>Sustained DP was defined as sustained increase of at least 1 point from baseline (EFC6049) EDSS score (0.5 point for participants with baseline EDSS&gt;5.5) persisting for at least 24 weeks. EDSS: an ordinal scale qualifies disability in participants with MS. EDSS total score range: 0 (normal neurological examination) to 10 (death due to MS). Probability of DP at 24 weeks was estimated using Kaplan-Meier method on time to DP defined as date of first DP minus (-) date of randomization in EFC6049 study +1 day. Participants free of DP (no DP observed on treatment) were censored at the date of last on-treatment EDSS evaluation in LTS6050. Kaplan-Meier method consists in computing probabilities of non-occurrence of event at any observed time of event and multiplying successive probabilities for time ≤t by any earlier computed probabilities to estimate the probability of being event-free for the amount of time t.</description>
          <population>Intent-to-treat (ITT) (EFC6049+ LTS6050) population: all participants randomized in both EFC6049 and LTS6050 studies that had at least 1-day IMP exposure during both EFC6049 and LTS6050 studies. Analysis for this outcome measure was performed on the combined data of EFC6049 andLTS6050 study, as pre-specified in the protocol.</population>
          <units>Probability</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="252"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.444" lower_limit="0.338" upper_limit="0.550"/>
                    <measurement group_id="O2" value="0.434" lower_limit="0.363" upper_limit="0.504"/>
                    <measurement group_id="O3" value="0.518" lower_limit="0.411" upper_limit="0.624"/>
                    <measurement group_id="O4" value="0.438" lower_limit="0.367" upper_limit="0.509"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using Log-rank test with treatment, EDSS strata at baseline and region as covariates. Estimation was performed using Cox proportional hazard model with treatment, EDSS strata at baseline and region as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8017</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.961</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.678</ci_lower_limit>
            <ci_upper_limit>1.362</ci_upper_limit>
            <estimate_desc>Placebo/Teriflunomide 7 mg vs. Teriflunomide 7 mg/7 mg</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using Log-rank test with treatment, EDSS strata at baseline and region as covariates. Estimation was performed using Cox proportional hazard model with treatment, EDSS strata at baseline and region as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1866</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.790</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.559</ci_lower_limit>
            <ci_upper_limit>1.117</ci_upper_limit>
            <estimate_desc>Placebo/Teriflunomide 14 mg vs. Teriflunomide 14 mg/14 mg</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using Log-rank test with treatment, EDSS strata at baseline and region as covariates. Estimation was performed using Cox proportional hazard model with treatment, EDSS strata at baseline and region as covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8763</p_value>
            <p_value_desc>Threshold for significance at 0.05 level.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.020</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.767</ci_lower_limit>
            <ci_upper_limit>1.357</ci_upper_limit>
            <estimate_desc>Teriflunomide 7 mg/7 mg vs. Teriflunomide 14 mg/14 mg</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Free of Sustained Disability Progression (DP)</title>
        <description>Sustained DP was defined as sustained increase of at least 1 point from baseline (EFC6049) EDSS score (0.5 point for participants with baseline EDSS&gt;5.5) persisting for at least 12 weeks and 24 weeks. EDSS is an ordinal scale in half-point increments that qualifies disability in participants with MS. It consists of 8 ordinal rating scales assessing seven functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder, cerebral) as well as ambulation. EDSS total score ranges from 0 (normal neurological examination) to 10 (death due to MS), where higher scores indicates worse neurological function. Percentage of participants who were considered as free of disability progression confirmed after 12 week sustained progression and 24 week sustained progression were reported. Analysis for this outcome measure was performed on combined data of EFC6049 and LTS6050 study, as pre-specified in protocol.</description>
        <time_frame>Up to 10.8 years since EFC6049 randomization (EFC6049: 108 weeks + LTS6050: 450 weeks)</time_frame>
        <population>Intent-to-treat (ITT) (EFC6049 [NCT00134563] + LTS6050) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Teriflunomide 7 mg</title>
            <description>Participants who completed treatment of placebo (for teriflunomide) tablet QD for 108 weeks in EFC6049 study, received teriflunomide tablet 7 mg QD for 288 weeks in this extension study.</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 7 mg/7 mg</title>
            <description>Participants who completed treatment of teriflunomide 7 mg tablet QD for 108 weeks in EFC6049 study, continued their treatment with teriflunomide 7 mg tablet QD for 288 weeks in this extension study.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Teriflunomide 14 mg</title>
            <description>Participants who completed treatment of placebo (for teriflunomide) tablet QD for 108 weeks in EFC6049, study received teriflunomide 14 mg tablet QD for 288 weeks in this extension study.</description>
          </group>
          <group group_id="O4">
            <title>Teriflunomide 14 mg/14 mg</title>
            <description>Participants who completed treatment of teriflunomide 14 mg tablet QD for 108 weeks in EFC6049 study, continued their treatment with teriflunomide 14 mg tablet QD for 288 weeks in this extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Free of Sustained Disability Progression (DP)</title>
          <description>Sustained DP was defined as sustained increase of at least 1 point from baseline (EFC6049) EDSS score (0.5 point for participants with baseline EDSS&gt;5.5) persisting for at least 12 weeks and 24 weeks. EDSS is an ordinal scale in half-point increments that qualifies disability in participants with MS. It consists of 8 ordinal rating scales assessing seven functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder, cerebral) as well as ambulation. EDSS total score ranges from 0 (normal neurological examination) to 10 (death due to MS), where higher scores indicates worse neurological function. Percentage of participants who were considered as free of disability progression confirmed after 12 week sustained progression and 24 week sustained progression were reported. Analysis for this outcome measure was performed on combined data of EFC6049 and LTS6050 study, as pre-specified in protocol.</description>
          <population>Intent-to-treat (ITT) (EFC6049 [NCT00134563] + LTS6050) population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="252"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Free of DP Sustained for 12 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.6"/>
                    <measurement group_id="O2" value="50.6"/>
                    <measurement group_id="O3" value="37.3"/>
                    <measurement group_id="O4" value="52.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free of DP Sustained for 24 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6"/>
                    <measurement group_id="O2" value="56.6"/>
                    <measurement group_id="O3" value="48.2"/>
                    <measurement group_id="O4" value="56.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annualized MS Relapse Rate (ARR): Poisson Regression Estimates</title>
        <description>ARR was obtained from total number of confirmed relapses that occurred during treatment period divided by sum of treatment durations in LTS6050 study only. Each episode of relapse - appearance, or worsening of a clinical symptom that was stable for at least 30 days, that persisted for a minimum of 24 hours in the absence of fever was to be confirmed by an increase in EDSS score or Functional System (FS) scores. EDSS: an ordinal scale qualifies disability. EDSS total score range: 0 (normal neurological examination) to 10 (death due to MS). FSS: to assess the neurological function. Total score range: 0 (normal) - 6(worse), higher scores = worse neurological function. To account for the different treatment duration among participants, a Poisson regression model with robust error variance was used (total number of confirmed relapses as response variable; log transformed treatment duration as &quot;offset&quot; variable; treatment group, region of enrolment and baseline EDSS stratum as covariates).</description>
        <time_frame>Up to 8 years since LTS6050 randomization</time_frame>
        <population>ITT(LTS6050) population: all participants who were randomized in the LTS6050 study and had at least 1-day IMP exposure during the LTS6050 study.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Teriflunomide 7 mg</title>
            <description>Participants who completed treatment of placebo (for teriflunomide) tablet QD for 108 weeks in EFC6049 study, received teriflunomide tablet 7 mg QD for 288 weeks in this extension study.</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 7 mg/7 mg</title>
            <description>Participants who completed treatment of teriflunomide 7 mg tablet QD for 108 weeks in EFC6049 study, continued their treatment with teriflunomide 7 mg tablet QD for 288 weeks in this extension study.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Teriflunomide 14 mg</title>
            <description>Participants who completed treatment of placebo (for teriflunomide) tablet QD for 108 weeks in EFC6049, study received teriflunomide 14 mg tablet QD for 288 weeks in this extension study.</description>
          </group>
          <group group_id="O4">
            <title>Teriflunomide 14 mg/14 mg</title>
            <description>Participants who completed treatment of teriflunomide 14 mg tablet QD for 108 weeks in EFC6049 study, continued their treatment with teriflunomide 14 mg tablet QD for 288 weeks in this extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized MS Relapse Rate (ARR): Poisson Regression Estimates</title>
          <description>ARR was obtained from total number of confirmed relapses that occurred during treatment period divided by sum of treatment durations in LTS6050 study only. Each episode of relapse - appearance, or worsening of a clinical symptom that was stable for at least 30 days, that persisted for a minimum of 24 hours in the absence of fever was to be confirmed by an increase in EDSS score or Functional System (FS) scores. EDSS: an ordinal scale qualifies disability. EDSS total score range: 0 (normal neurological examination) to 10 (death due to MS). FSS: to assess the neurological function. Total score range: 0 (normal) - 6(worse), higher scores = worse neurological function. To account for the different treatment duration among participants, a Poisson regression model with robust error variance was used (total number of confirmed relapses as response variable; log transformed treatment duration as &quot;offset&quot; variable; treatment group, region of enrolment and baseline EDSS stratum as covariates).</description>
          <population>ITT(LTS6050) population: all participants who were randomized in the LTS6050 study and had at least 1-day IMP exposure during the LTS6050 study.</population>
          <units>relapses per participant-year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="252"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.216" lower_limit="0.162" upper_limit="0.288"/>
                    <measurement group_id="O2" value="0.183" lower_limit="0.149" upper_limit="0.225"/>
                    <measurement group_id="O3" value="0.176" lower_limit="0.132" upper_limit="0.236"/>
                    <measurement group_id="O4" value="0.160" lower_limit="0.129" upper_limit="0.198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Magnetic Resonance Imaging (MRI) Assessment: Change From Baseline in Total Volume of Abnormal Lesions (Burden of Disease [BOD]) at Week 192 Since LTS6050 Randomization</title>
        <description>BOD was assessed by cerebral MRI and defined as the total volume of all abnormal brain tissue (calculated as the sum of the total volume of T2-lesion component and T1-hypointense lesion component).</description>
        <time_frame>Baseline, Week 192</time_frame>
        <population>ITT (LTS6050 population). Number of participants analyzed=participants with available data for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Teriflunomide 7 mg</title>
            <description>Participants who completed treatment of placebo (for teriflunomide) tablet QD for 108 weeks in EFC6049 study, received teriflunomide tablet 7 mg QD for 288 weeks in this extension study.</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 7 mg/7 mg</title>
            <description>Participants who completed treatment of teriflunomide 7 mg tablet QD for 108 weeks in EFC6049 study, continued their treatment with teriflunomide 7 mg tablet QD for 288 weeks in this extension study.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Teriflunomide 14 mg</title>
            <description>Participants who completed treatment of placebo (for teriflunomide) tablet QD for 108 weeks in EFC6049, study received teriflunomide 14 mg tablet QD for 288 weeks in this extension study.</description>
          </group>
          <group group_id="O4">
            <title>Teriflunomide 14 mg/14 mg</title>
            <description>Participants who completed treatment of teriflunomide 14 mg tablet QD for 108 weeks in EFC6049 study, continued their treatment with teriflunomide 14 mg tablet QD for 288 weeks in this extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Magnetic Resonance Imaging (MRI) Assessment: Change From Baseline in Total Volume of Abnormal Lesions (Burden of Disease [BOD]) at Week 192 Since LTS6050 Randomization</title>
          <description>BOD was assessed by cerebral MRI and defined as the total volume of all abnormal brain tissue (calculated as the sum of the total volume of T2-lesion component and T1-hypointense lesion component).</description>
          <population>ITT (LTS6050 population). Number of participants analyzed=participants with available data for this outcome measure.</population>
          <units>millilitres (ml)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.307" spread="9.088"/>
                    <measurement group_id="O2" value="3.969" spread="11.135"/>
                    <measurement group_id="O3" value="3.720" spread="6.696"/>
                    <measurement group_id="O4" value="3.943" spread="9.685"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All AEs were collected from signature of informed consent form up to 28 days after the last dose of study drug up to Week 450, regardless of seriousness or relationship to investigational product</time_frame>
      <desc>Reported AEs are TEAEs that is AEs that developed/worsened during the ‘on treatment period’ (the time from the first dose of study treatment up to 4 weeks [28 days] after the last dose of study treatment). Analysis was performed on safety population and was conducted as per the treatment received.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo/Teriflunomide 7 mg</title>
          <description>Participants who completed treatment of placebo (for teriflunomide) tablet QD for 108 weeks in EFC6049 study, received teriflunomide tablet 7 mg QD for 288 weeks in this extension study.</description>
        </group>
        <group group_id="E2">
          <title>Teriflunomide 7 mg/7 mg</title>
          <description>Participants who completed treatment of teriflunomide 7 mg tablet QD for 108 weeks in EFC6049 study, continued their treatment with teriflunomide 7 mg tablet QD for 288 weeks in this extension study.
Included 2 participants randomized in placebo and teriflunomide 14 mg arm respectively in EFC6049 study, incorrectly received at least 1 dose of teriflunomide 7 mg. In LTS6050 study, same participants received correct dose of teriflunomide 14 mg but included in Teriflunomide 7mg/7 mg arm for safety analysis.</description>
        </group>
        <group group_id="E3">
          <title>Placebo/Teriflunomide 14 mg</title>
          <description>Participants who completed treatment of placebo (for teriflunomide) tablet QD for 108 weeks in EFC6049, study received teriflunomide 14 mg tablet QD for 288 weeks in this extension study.
Excluded 1 participant randomized in placebo arm in EFC6049 study, incorrectly received at least 1 dose of teriflunomide 7 mg. In LTS6050 study, same participant received 14 mg dose but included in teriflunomide 7 mg/7 mg arm for safety analysis.</description>
        </group>
        <group group_id="E4">
          <title>Teriflunomide 14 mg/14 mg</title>
          <description>Participants who completed treatment of teriflunomide 14 mg tablet QD for 108 weeks in EFC6049 study, continued their treatment with teriflunomide 14 mg tablet QD for 288 weeks in this extension study.
Excluded 1 participant randomized in 14 mg arm in EFC6049 study, incorrectly received at least 1 dose of teriflunomide 7 mg. In LTS6050 study, same participant received correct dose of 14 mg but included in Teriflunomide 7mg/7 mg arm for safety analysis.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA-18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="62" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Cardiac valve disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Dolichocolon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Cystoid macular oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Gastrointestinal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Mechanical ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Colitis microscopic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Gastroduodenal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Hernial eventration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Mesenteric haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Mouth swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Hepatocellular injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Endometritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Hepatitis A</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Bone abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Bursitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Infected dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Tubo-ovarian abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Anastomotic leak</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Hepatic rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Traumatic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Bone cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Cholesteatoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the cervix</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Paraplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Uhthoff's phenomenon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Ageusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Cerebrovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Facial neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Muscle spasticity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Posterior reversible encephalopathy syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Bladder prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Renal mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Breast hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Breast cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Cervical polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Premenstrual cramps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia areata</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Lichen planus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Pustular psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Miscarriage of partner</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Mammoplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Osteotomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Venous stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA-18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="195" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="95" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="197" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="81" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="254"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="107"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Trial Transparency Team</name_or_title>
      <organization>Sanofi</organization>
      <email>Contact-US@sanofi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

